Mark Hazeltine's most recent trade in Exagen Inc was a trade of 3,667 Common Stock done . Disclosure was reported to the exchange on March 2, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Exagen Inc | Mark Hazeltine | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 02 Mar 2023 | 3,667 | 190,205 (1%) | 0% | 0 | Common Stock | |
| Exagen Inc | Mark Hazeltine | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2023 | 100,000 | 193,872 (1%) | 0% | 0 | Common Stock | |
| Exagen Inc | Mark Hazeltine | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 2.69 per share. | 08 Feb 2023 | 5,821 | 93,872 (0%) | 0% | 2.7 | 15,672 | Common Stock |
| Exagen Inc | Mark Hazeltine | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.12 per share. | 01 Mar 2022 | 3,241 | 99,693 (0%) | 0% | 7.1 | 23,076 | Common Stock |
| Exagen Inc | Mark Hazeltine | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 63,500 | 102,934 (0%) | 0% | 0 | Common Stock |